Help patients who

have had a recent

worsening heart

failure event stay alive

and out of hospital

Help patients who

have had a recent

worsening heart

failure event stay alive

and out of hospital

Help patients who

have had a recent

worsening heart

failure event stay alive

and out of hospital

1 / 3

Discover sGC stimulation as a new mechanism in HF treatment

VERQUVO provides a novel HF therapy that has demonstrated powerful reductions in the composite of CV death and HF hospitalization compared to background therapies alone.

In patients with chronic HF after a worsening event, VERQUVO reduced the absolute risk of CV death and HF hospitalization combined by

4.2% (ARR)
compared to background therapy alone.

In only 10.8 months, VERQUVO reduced the combined relative risk of CV death and HF hospitalization by 10% (RRR) in chronic HF patients following a worsening HF event.

Treating just 24 chronic HF patients with VERQUVO for one year can prevent one HF hospitalization, or even save a life (NNT 24).

CV death and HFH combined

CV death and HFH combined

VERQUVO provided significant risk reduction in patients with NT-proBNP levels frequently seen in clinical practice

For your chronic HFrEF patients who have had a worsening HF event, consider the role that once daily VERQUVO can play to reduce the risk of another event, hospitalization or CV death.

Reduce the combined risk of death from any cause or rehospitalization following a worsening HF event with VERQUVO

Patients with chronic HF need new therapies to further reduce their risk, whilst delivering a reassuring safety profile.

Improve your patients' chances of staying alive and out of hospital following a worsening HF event by adopting a therapy that will significantly reduce their risk of another event.

Verquvo data
Decompensation

Adapted from Greene SJ et al. JAMA Cardiol 2018;3(3):252–259

Worsening HF event risk signals a need for treatment modification

Did your patient need time in hospital or additional treatment like IV diuretics? They may have suffered a worsening HF event.

Following a worsening HF event, patients are at even higher risk of cardiovascular disease and re-hospitalization

They experience a devastating cycle of escalating symptoms and frequent hospitalizations, which severely affects their lives as well as the lives of their loved ones.

    Referencesexpand_less
    • 1
      Armstrong PW, Pieske B, Anstrom KJ et al. VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893.
    • 2
      Verquvo (Prescription Information) India, Based on CCDS v03 dated 15 Feb 2023 and US indication statement approved dated 19-Jan-2021 Revision: Sep 2023
    • 3
      Armstrong PW, Roessig L, Patel MJ et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 2018;6(2):96–104.
    • 4
      Pieske B, Butler J, Filippatos G et al. SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16(9):1026–1038.
    • 5
      Senni M, Lopez-Sendon J, Cohen-Solal A et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail. 2022;9(6):3791–3803.
    • 6
      Januzzi JL, Tan X, Yang L et al. N-terminal pro-B-type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2022;(1):87–99.
    • 7
      Greene SJ, Butler J, Fonarow GC. Contextualizing Risk Among Patients With Heart Failure. JAMA. 2021;326(22):2261–2262.
    • 8
      Greene SJ, Bauersachs J, Brugts JJ et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81(4):413–424.
    • 9
      ESC. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2016) 37, 2129–2200.
    • 10
      Jaarsma T, Hill L, Bayes‐Genis A, et al. Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2021 Jan;23(1):157-74.
    • 11
      Lavalle C, Di Lullo L, Jabbour JP, et al. New challenges in heart failure with reduced ejection fraction: managing worsening events. Journal of Clinical Medicine. 2023 Nov 7;12(22):6956.